Zacks Investment Research lowered shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a buy rating to a hold rating in a research note published on Monday.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
Several other research firms have also recently commented on ATNM. Maxim Group reiterated a buy rating and set a $3.00 target price on shares of Actinium Pharmaceuticals in a research note on Wednesday, October 25th. HC Wainwright reiterated a buy rating and set a $6.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. B. Riley set a $3.00 target price on Actinium Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, December 12th. Finally, Roth Capital reiterated a buy rating and set a $6.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus target price of $3.75.
ILLEGAL ACTIVITY WARNING: “Actinium Pharmaceuticals (ATNM) Downgraded to “Hold” at Zacks Investment Research” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2018/01/09/actinium-pharmaceuticals-atnm-downgraded-to-hold-at-zacks-investment-research.html.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.